Search

Displaying results 2991 - 3000 of 6835 in total
  1. Drug

    Enoximone

    go.drugbank.com/drugs/DB04880
    ApprovedInvestigationalWithdrawn

    Trials were halted in the U.S., but the drug is used in various countries.

  2. Drug

    Rimexolone

    go.drugbank.com/drugs/DB00896
    ApprovedWithdrawn

    It is used to treat inflammation in the eye. It is marketed as Vexol.

  3. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation

    Synonyms: Ig heavy chain V-III region BUR
  4. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    [A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin … [L51254] It is designed to deliver diphtheria toxin into IL-2 receptor-expressing cancer cells to cause cell death.

  5. Drug

    Zanamivir

    go.drugbank.com/drugs/DB00558
    ApprovedInvestigational

    A guanido-neuraminic acid that is used to inhibit neuraminidase.

  6. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. … Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.

  7. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  8. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  9. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB21765
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  10. Drug

    Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen

    go.drugbank.com/drugs/DB17995
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes